Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
(MedPage Today) -- For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the "preferred" systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Colorectal Cancer | Gastroenterology | Liver | Urology & Nephrology